The impact of dynamic kidney function prior to using sodium–glucose cotransporter‐2 inhibitors in type 2 diabetes patients with low‐risk renal disease progression
Journal of Diabetes Investigation · 2025
DOI: 10.1111/jdi.70180 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetes Investigation, 2025. Verfasst von Yen-Chen Chiu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Master Degree Program in Clinical Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Kidney. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims/Introduction Few studies have assessed whether dynamic kidney function prior to sodium–glucose cotransporter‐2 inhibitor (SGLT2i) initiation influenced subsequent renal outcomes. Thus, the study aimed to investigate whether combining estimated glomerular filtration rate (eGFR) slope and urinary albumin/creatinine ratio (UACR) change prior to using SGLT2i contributes to subsequent kidney outcomes. Materials and Methods This retrospective cohort study utilized data from the Kaohsiung Medical University Hospital Research Database (KMUHRD) in Taiwan. We identified 975 SGLT2i new users with type 2 diabetes from 2016 to 2020, who had an eGFR >60 mL/min/1.73 m 2 and UACR 30% eGFR decline with a drop in eGFR categories and a >43% UACR increase with progression in UACR categories.
Results
After SGLT2i treatment, compared with the non‐progressive renal function group, the glomerular injury group significantly lowered the risk of eGFR decline (adjusted hazard ratio [95% CI] 0.384 [0.199, 0.740]) and UACR progression (adjusted hazard ratio [95% CI] 0.514 [0.313, 0.846]). In addition, for those with a major eGFR decline before starting SGLT2i, significant improvements in the eGFR slope ( P < 0.05) were observed after the treatment, irrespective of UACR increase.
Conclusions
Early initiation of SGLT2i among type 2 diabetes patients with low‐risk renal disease progression and glomerular injury renal status may prevent them from progressing into chronic kidney disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Master Degree Program in Clinical Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.
- College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
- College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Department of Pharmacy, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
ORCID-Profile: Yaw-Bin Huang
Zitieren
APA
Chiu, Y. C., Singhan, W., Chinwong, S., Chinwong, D., Hwang, S. J., & Huang, Y. B. (2025). The impact of dynamic kidney function prior to using sodium–glucose cotransporter‐2 inhibitors in type 2 diabetes patients with low‐risk renal disease progression. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.70180
Vancouver
Chiu YC, Singhan W, Chinwong S, Chinwong D, Hwang SJ, Huang YB. The impact of dynamic kidney function prior to using sodium–glucose cotransporter‐2 inhibitors in type 2 diabetes patients with low‐risk renal disease progression. Journal of Diabetes Investigation. 2025. doi:10.1111/jdi.70180
BibTeX
@article{Chiu2025,
author = {Chiu, Yen-Chen and Singhan, Wanchana and Chinwong, Surarong and Chinwong, Dujrudee and Hwang, Shang-Jyh and Huang, Yaw-Bin},
title = {The impact of dynamic kidney function prior to using sodium–glucose cotransporter‐2 inhibitors in type 2 diabetes patients with low‐risk renal disease progression},
journal = {Journal of Diabetes Investigation},
year = {2025},
doi = {10.1111/jdi.70180}
}
EUVIMED